Louisiana pharmacy CEO pleads guilty to $50M reimbursement fraud

Hayley Taff, CEO of Hammond, La.-based pharmacy Central Rexall Drugs, pleaded guilty Aug. 12 to playing a key role in a scheme that garnered more than $50 million in false reimbursements.

Advertisement

Ms. Taff and her co-conspirators recruited public employees in New Jersey to get pricey specialty prescriptions they had not been prescribed, according to U.S. Attorney Craig Carpenito of the District of New Jersey.

Recruiters told the patients which medications to get based on how much reimbursement the pharmacy would receive from insurance companies for the drugs, not because the patients needed them, Mr. Carpenito said. The drugs covered within these New Jersey workers’ insurance plans included expensive pain, antifungal, scar and libido medications with reimbursements that often ran as high as thousands of dollars per month, WNBC reported.

Central Rexall Drugs was paid more than $50 million in reimbursements from pharmacy benefits managers from 2015 to 2016, according to Mr. Carpenito. He also said Ms. Taff, who will be sentenced Dec. 1, received more than $1.5 million from the scheme.

Ms. Taff pleaded guilty to conspiracy to commit healthcare fraud and agreed to pay back more than $1.5 million, authorities said. She could face up to 10 years in prison.

More articles on pharmacy:
Merck bets on one-shot vaccine
US signs $1.5B deal for 100 million doses of Moderna’s coronavirus vaccine candidate
Virginia pharmacy school files suit against accreditation agency, calls process ‘bizarrely contradictory and Kafkaesque’

Advertisement

Next Up in Pharmacy

  • The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

  • From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

  • In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

Advertisement

Comments are closed.